参考文献/References:
[1] HARDY J, ALLSOP D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease[J]. Trends in Pharmacological Sciences, 1991, 12(10): 383-388.
[2] WANG X L, SU B, SIEDLAK S L, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins[J]. PNAS, 2008, 105(49): 19318-19323.
[3] MACIAS M P, GONZALES A M, SINIARD A L, et al. A cellular model of amyloid precursor protein processing and amyloid-β peptide production[J]. Journal of Neuroscience Methods, 2014, 223: 114-122.
[4] ANDRES D, KEYSER B M, PETRALI J, et al. Morphological and functional differentiation in BE(2)-M17 human neuroblastoma cells by treatment with trans-retinoic acid[J]. BMC Neuroscience, 2013, 14: 49.
[5] WANG X L, SU B, LEE H G, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease[J]. The Journal of Neuroscience, 2009, 29(28): 9090-9103.
[6] HAN X, NONAKA K, KATO H, et al. Osteoblastic differentiation improved by bezafibrate-induced mitochondrial biogenesis in deciduous tooth-derived pulp stem cells from a child with leigh syndrome[J]. Biochemistry and Biophysics Reports, 2019, 17: 32-37.
[7] RAMIREZ-ESPINOSA J J, GONZALEZ-DAVALOS L, SHIMADA A, et al. Bovine(bos taurus)bone marrow mesenchymal cell differentiation to adipogenic and myogenic lineages[J]. Cells, Tissues, Organs, 2016, 201(1): 51-64.
[8] AUGUSTYNIAK J, LENART J, GAJ P, et al. Bezafibrate upregulates mitochondrial biogenesis and influence neural differentiation of human-induced pluripotent stem cells[J]. Molecular Neurobiology, 2019, 56(6): 4346-4363.
[9] JOHRI A, CALINGASAN N Y, HENNESSEY T M, et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease[J]. Human Molecular Genetics, 2011, 21(5): 1124-1137.
[10] KREISLER A, DUHAMEL A, VANBESIEN-MAILLIOT C, et al. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease[J]. Behavioural Pharmacology, 2010, 21(3): 194-205.
[11] AGARWAL S, YADAV A, CHATURVEDI R K. Peroxisome proliferator-activated receptors(PPARs)as therapeutic target in neurodegenerative disorders[J]. Biochemical and Biophysical Research Communications, 2017, 483(4): 1166-1177.
[12] KOCH A, THIEMANN M, GRABENBAUER M, et al. Dynamin-like protein 1 is involved in peroxisomal fission[J]. Journal of Biological Chemistry, 2003,278(10): 8597-8605.
[13] SHENG B Y, WANG X L, SU B, et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease[J]. Journal of Neurochemistry, 2012, 120(3): 419-429.
[14] ZHONG X, XIU L L, WEI G H, et al. Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation[J]. Acta Pharmacologica Sinica, 2011, 32(5): 591-600.
[15] PENG K G, YANG L K, WANG J, et al. The interaction of mitochondrial biogenesis and fission/fusion mediated by PGC-1α regulates rotenone-induced dopaminergic neurotoxicity[J]. Molecular Neurobiology, 2017, 54(5): 3783-3797.